Vaccinex Adds $25 Million

Vaccinex Inc., a Rochester, N.Y.-based developer of antibodies, has raised $25 million in Series B-2 funding, according to VentureWire. Teva Pharmaceuticals and Pan Atlantic Bank & Trust co-led the round, and were joined by return backers like Biocon and Toronto Investment Group. www.vaccinex.com